Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT00686699 Terminated - Clinical trials for Parkinsonian Disorders

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Start date: July 10, 2006
Phase: Phase 2
Study type: Interventional

This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder. Participants were to be evaluated for two 14-day treatment periods with a 3-week washout period between treatment periods. The primary outcome measure, Extrapyramidal Symptom Rating Score (ESRS), was to be evaluated frequently during the treatment periods.

NCT ID: NCT00685815 Completed - Restless Legs Clinical Trials

Intravenous Iron Metabolism in Restless Legs Syndrome

Start date: November 2006
Phase: Phase 2
Study type: Interventional

To determine the effects of high-dose infusions of iron on Restless Legs Syndrome (RLS) symptoms and brain concentrations of iron.

NCT ID: NCT00676403 Completed - Clinical trials for Restless Legs Syndrome

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

Start date: April 2008
Phase: Phase 2
Study type: Interventional

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

NCT ID: NCT00666965 Completed - Clinical trials for Idiopathic Restless Legs Syndrome

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple transdermal doses of SPM 962 within a range of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.

NCT ID: NCT00656110 Recruiting - Clinical trials for Restless Legs Syndrome

Neuroma Injections to Treat Restless Legs Syndrome - RCT

Start date: April 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether, in a randomized, placebo-controlled trial, restless legs syndrome (RLS) can be caused by pinched and damaged foot nerves called neuromas.

NCT ID: NCT00654498 Completed - Clinical trials for Restless Legs Syndrome

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Start date: April 2008
Phase: Phase 3
Study type: Interventional

To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)

NCT ID: NCT00628589 Completed - Clinical trials for Schizophrenic Patients With Acute Agitation

Staccato® Loxapine Treatment of Schizophrenic Patients With Agitation

Start date: February 2008
Phase: Phase 3
Study type: Interventional

Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients

NCT ID: NCT00627003 Completed - Clinical trials for Restless Legs Syndrome

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

Start date: November 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS. Also, additional objective and subjective sleep parameters and quality of life will be assessed.

NCT ID: NCT00626418 Completed - Clinical trials for Restless Legs Syndrome

The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and tolerability of single doses of aplindore compared to placebo in RLS. Patients will be required to spend 5-8 nights in a sleep laboratory. This includes 1 adaptation night, 1 placebo night, and 3-6 drug treatment nights. Ascending doses of active drug will be administered on study nights 3 through 5 to determine the maximum well tolerated efficacious dose (defined as a decrease in Periodic Limb Movement Index (PLMI) of at least 50% from placebo baseline). If an efficacious dose cannot be identified the Investigator in consultation with the sponsor may decide to examine higher doses in up to 3 additional PSG nights in an attempt to identify a tolerable efficacious dose. This study will utilize up to 24 evaluable patients, each meeting International Classification of Sleep Disorders (ICSD-2) diagnostic criteria for primary RLS who are not currently taking any RLS medication including DAs ( and L-dopa) or who are able to discontinue their RLS medication at least 5 half-lives prior to the adaptation night.

NCT ID: NCT00625547 Completed - Clinical trials for Restless Legs Syndrome

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.